Article

Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: Potent and selective nonsteroidal inhibitors of 17 beta-hydroxysteroid dehydrogenase type 1 (17 beta-HSD1) for the treatment of estrogen-dependent diseases

8.2 Pharmaceutical and Medicinal Chemistry, Saarland University, Saarbrücken, Germany.
Journal of Medicinal Chemistry (Impact Factor: 5.48). 05/2008; 51(7):2158-69. DOI: 10.1021/jm701447v
Source: PubMed

ABSTRACT Human 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) catalyzes the reduction of the weak estrogen estrone (E1) to the highly potent estradiol (E2). This reaction takes place in the target cell where the estrogenic effect is exerted via the estrogen receptor (ER). Estrogens, especially E2, are known to stimulate the proliferation of hormone-dependent diseases. 17beta-HSD1 is overexpressed in many breast tumors. Thus, it is an attractive target for the treatment of these diseases. Ligand- and structure-based drug design led to the discovery of novel, selective, and potent inhibitors of 17beta-HSD1. Phenyl-substituted bicyclic moieties were synthesized as mimics of the steroidal substrate. Computational methods were used to obtain insight into their interactions with the protein. Compound 5 turned out to be a highly potent inhibitor of 17beta-HSD1 showing good selectivity (17beta-HSD2, ERalpha and beta), medium cell permeation, reasonable metabolic stability (rat hepatic microsomes), and little inhibition of hepatic CYP enzymes.

1 Follower
 · 
137 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Suzuki-Miyaura cross-coupling reactions of heteroaromatics catalyzed by palladium supported in the cavities of amino-functionalized silicious mesocellular foam is presented. The nanopalladium catalyst effectively couples not only heteroaryl halides with boronic acids, but also heteroarylboronic acids, boronate esters, potassium trifluoroborates, MIDA boronates and triolborates, producing heterobiaryls in good to excellent yields. Furthermore, the heterogenous palladium nanocatalyst can easly be removed from the reaction mixture by filtration and recycled several times with minimal loss in activity. This catalyst provides an alternative, environmentally friendly, low-leaching process for the preparation of heterobiaryls.
    The Journal of Organic Chemistry 03/2014; 79(9). DOI:10.1021/jo500409r · 4.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: 17β-Hydroxysteroid dehydrogenase type 2 (17β-HSD2) catalyses the conversion of active 17β-hydroxysteroids into the less active 17-ketosteroids thereby controlling the availability of biologically active estrogens (E2) and androgens (T) in the tissues. The skeletal disease osteoporosis occurs mainly in post-menopausal women and in elderly men when the levels of estrogens and androgens, respectively, decrease. Since 17β-HSD2 is present in osteoblasts, inhibition of this enzyme may provide a new and promising approach to prevent the onset of osteoporosis, keeping a certain level in estrogens and androgens in bone cells of ageing people. Hydroxynaphthyl, hydroxyphenyl and hydroxymethylphenyl-substituted moieties were synthesised as mimetics of the steroidal substrate. Compound 8 has been identified as promising scaffold for 17β-HSD2 inhibitors displaying high activity and good selectivity toward 17β-HSD1, ERα and ERβ.
    Bioorganic & medicinal chemistry 01/2011; 19(2):807-15. DOI:10.1016/j.bmc.2010.12.013 · 2.95 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: A series of 23 N-(Pyridin-3-yl)benzamides was synthesized and evaluated for their potential to inhibit human steroid-11β-hydroxylase (CYP11B1) and human aldosterone synthase (CYP11B2). The most potent and selective CYP11B2 inhibitors (IC(50) values 53-166 nM) were further evaluated for their potential to inhibit human CYP17 and CYP19, and no inhibition was observed. Clear evidence was shown for N-(Pyridin-3-yl)benzamides to be a highly selective class of CYP11B2 inhibitors in vitro.
    Bioorganic & medicinal chemistry letters 01/2011; 21(1):186-90. DOI:10.1016/j.bmcl.2010.11.040 · 2.33 Impact Factor